Efficacy of ursodeoxycholic acid treatment and endoscopic dilation of major duct stenoses in primary sclerosing cholangitis. An 8-year prospective study
- PMID: 9075663
- DOI: 10.1016/s0168-8278(97)80421-7
Efficacy of ursodeoxycholic acid treatment and endoscopic dilation of major duct stenoses in primary sclerosing cholangitis. An 8-year prospective study
Abstract
Background/aims: Primary sclerosing cholangitis is characterized by progressive fibrotic inflammation and obliteration of intra- and extrahepatic bile ducts. Ursodeoxycholic acid treatment leads to improvement of biochemical parameters of cholestasis and in part also of liver histology. During treatment, obstruction of major ducts may lead to deterioration of liver function, which may be prevented by endoscopic dilation of the stenoses. Controlled trials for evaluation of the beneficial effects of ursodeoxycholic acid treatment and of endoscopic measures in patients with major duct stenoses have become clinically difficult. Estimation of survival probabilities without treatment allows comparison of actuarial survival with the estimated survival probabilities.
Methods/results: We studied survival in 65 patients with PSC treated with ursodeoxycholic acid (750 mg/day) and by endoscopic measures whenever necessary. Patients with decompensated cirrhosis in whom transplantation was foreseen were excluded. The study was started in May 1987 and the mean follow-up period was 45.0+/-3.5 (mean+/-SEM) months. Liver histology was performed in each of the patients before entry into the study and revealed that 21% were in stage 1, 37% in stage 2, 21% in stage 3 and 20% in stage 4. Of 65 patients, 12 had major duct stenosis at entry and another 11 developed major duct stenosis during ursodeoxycholic acid treatment, which was successfully treated by repeated endoscopic balloon dilations. The actuarial Kaplan-Meier survival probabilities without liver transplantation after treatment with ursodeoxycholic acid and dilation of major duct stenoses were significantly improved compared to the predicted survival rates with p=0.001.
Conclusions: Ursodeoxycholic acid does not prevent major bile duct occlusion. When ursodeoxycholic acid treatment and endoscopic opening of duct stenoses are combined, survival may be significantly improved.
Similar articles
-
Development of dominant bile duct stenoses in patients with primary sclerosing cholangitis treated with ursodeoxycholic acid: outcome after endoscopic treatment.J Hepatol. 2002 Feb;36(2):151-6. doi: 10.1016/s0168-8278(01)00251-3. J Hepatol. 2002. PMID: 11830325 Clinical Trial.
-
Endoscopic dilation of dominant stenoses in primary sclerosing cholangitis: outcome after long-term treatment.Gastrointest Endosc. 2010 Mar;71(3):527-34. doi: 10.1016/j.gie.2009.10.041. Gastrointest Endosc. 2010. PMID: 20189511
-
Ursodeoxycholic acid therapy for primary sclerosing cholangitis: results of a 2-year randomized controlled trial to evaluate single versus multiple daily doses.J Hepatol. 1998 Sep;29(3):417-23. doi: 10.1016/s0168-8278(98)80059-7. J Hepatol. 1998. PMID: 9764988 Clinical Trial.
-
Primary sclerosing cholangitis.Can J Gastroenterol. 2000 Apr;14(4):311-5. doi: 10.1155/2000/983681. Can J Gastroenterol. 2000. PMID: 10799084 Review.
-
Endoscopic treatment of dominant stenoses in patients with primary sclerosing cholangitis.Clin Rev Allergy Immunol. 2005 Apr;28(2):159-65. doi: 10.1385/CRIAI:28:2:159. Clin Rev Allergy Immunol. 2005. PMID: 15879621 Review.
Cited by
-
Bezafibrate may attenuate biliary damage associated with chronic liver diseases accompanied by high serum biliary enzyme levels.J Gastroenterol. 2006 Jul;41(7):686-92. doi: 10.1007/s00535-006-1831-0. J Gastroenterol. 2006. PMID: 16933007 Clinical Trial.
-
[Influence of technical advancements on the management of biliary tract diseases].Wien Med Wochenschr. 2006 Jul;156(13-14):386-90. doi: 10.1007/s10354-006-0313-6. Wien Med Wochenschr. 2006. PMID: 16937040 Review. German.
-
The management of primary sclerosing cholangitis.Curr Gastroenterol Rep. 2003 Feb;5(1):9-17. doi: 10.1007/s11894-003-0004-z. Curr Gastroenterol Rep. 2003. PMID: 12530943 Review.
-
Current Therapeutics in Primary Sclerosing Cholangitis.J Clin Transl Hepatol. 2023 Oct 28;11(5):1267-1281. doi: 10.14218/JCTH.2022.00068S. Epub 2023 Apr 17. J Clin Transl Hepatol. 2023. PMID: 37577219 Free PMC article. Review.
-
Effect of scheduled endoscopic dilatation of dominant strictures on outcome in patients with primary sclerosing cholangitis.Gut. 2019 Dec;68(12):2170-2178. doi: 10.1136/gutjnl-2018-316801. Epub 2019 Mar 25. Gut. 2019. PMID: 30910856 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources